Cisatracurium Besylate Injection shortage
Cisatracurium Besylate Injection is currently listed in shortage by the FDA. The FDA lists 3 affected products. This page was last refreshed from FDA data on Oct 2, 2026.
Pfizer (Hospira) is permanently stopping production of cisatracurium besylate injection, with remaining supply expected to run out by mid-to-late 2026. The same medicine is still listed by other manufacturers, including Hikma, Sandoz, Camber, and Eugia.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Cisatracurium Besylate Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 11, 2026Currently in shortage3 of 3 products affected.
-
Sep 11, 2026More presentations reported1 more product added to the shortage.
-
May 6, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02) | — | — | Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) | — | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01) | — | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Cisatracurium Besylate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Cisatracurium Besylate Injection? options further down this page.
Why is Cisatracurium Besylate Injection in shortage?
Hospira (a Pfizer company) has decided to permanently stop making all three of their cisatracurium besylate injection products. They haven't shared a specific public reason for this decision. The existing supply they have on hand is expected to run out on these timelines:
- 20 mg/10 mL (2 mg/mL) multidose vial — supply expected to run out late June 2026
- 200 mg/20 mL (10 mg/mL) single-dose vial — supply expected to run out late June 2026
- 10 mg/5 mL (2 mg/mL) single-dose vial — supply expected to run out November 2026
Once those supplies are gone, Hospira will no longer be producing any of these presentations. It's worth knowing that this report only covers Hospira's products specifically — it doesn't speak to what other manufacturers may or may not have available.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Cisatracurium Besylate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Cisatracurium Besylate Injection?
Cisatracurium Besylate Injection is currently on the FDA drug-shortage list. This is a hospital medicine given during anesthesia, so it is handled by your care team rather than picked up at a retail pharmacy — but I want to explain what the report shows clearly.
The record covers one manufacturer, Hospira (a Pfizer company), and it lists all three strengths as having no available source going forward: the 10 mg/5 mL (2 mg/mL) single-dose vial, the 20 mg/10 mL (2 mg/mL) multidose vial, and the 200 mg/20 mL (10 mg/mL) single-dose vial. The reason given is that this manufacturer is discontinuing its version of the drug, with remaining supply expected to run out in late June 2026 and, for one strength, November 2026. Because this is a planned discontinuation, this particular supply may not return — but this report reflects only one maker, and other companies still list the same medicine.
Here is what can help:
- Do not stop or change any dose on your own — this medicine is always managed by your medical team.
- Ask your prescriber or pharmacy team whether the same medicine can be sourced from another maker; the same ingredient and form is listed from suppliers including Hikma, Sandoz, Camber, Eugia, Fresenius Kabi, Caplin Steriles, and Somerset, though local stock can vary.
- Manufacturer contact numbers are listed on this page for reference.
This is general, national, manufacturer-reported information and may not match what any given facility has on hand.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Cisatracurium Besylate Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Cisatracurium Besylate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 10 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9160-10 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 2 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9396-01 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 2 mg/mL | Injection · Intravenous | Sandoz Inc | 00781-3150-95 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 10 mg/mL | Injection · Intravenous | Sandoz Inc | 00781-3153-95 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 10 mg/mL | Injection · Intravenous | Camber Pharmaceuticals Inc. | 31722-0312-10 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 2 mg/mL | Injection · Intravenous | Camber Pharmaceuticals Inc. | 31722-0313-10 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 10 mg/5mL | Injection · Intravenous | Eugia US LLC | 55150-0284-10 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 20 mg/10mL | Injection · Intravenous | Eugia US LLC | 55150-0286-10 |
| Cisatracurium | CISATRACURIUM BESYLATE 2 mg/mL | Injection, Solution · Intravenous | Fresenius Kabi USA, LLC | 63323-0416-05 |
| Cisatracurium | CISATRACURIUM BESYLATE 10 mg/mL | Injection, Solution · Intravenous | Fresenius Kabi USA, LLC | 63323-0418-20 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 10 mg/mL | Injection · Intravenous | Caplin Steriles Limited | 65145-0137-01 |
| Cisatracurium Besylate | CISATRACURIUM BESYLATE 2 mg/mL | Injection · Intravenous | Somerset Therapeutics, LLC | 70069-0141-01 |
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Cisatracurium Besylate 2 mg/mL | Hikma | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Hospira, | 10 vials | — | AP | FDA listed |
| cisatracurium besylate 2 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Camber | 10 vials | — | AP | FDA listed |
| Cisatracurium Besylate 10 mg/5mL | Eugia | 10 vials | — | — | FDA listed |
| Cisatracurium 2 mg/mL | Fresenius | 10 vials | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Caplin | 1 vial | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Somerset | 1 vial | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Slate | 10 vials | — | AP | FDA listed |
| cisatracurium besylate 2 mg/mL | Zydus | 10 vials | — | AP | FDA listed |
| Cisatracurium Besylate 10 mg/5mL | Meitheal | 10 vials | — | AP | FDA listed |
| cisatracurium besylate 2 mg/mL | Zydus | 10 vials | — | AP | FDA listed |
| Cisatracurium 2 mg/mL | Fresenius | 10 vials | — | AP | FDA listed |
| cisatracurium besylate 2 mg/mL | Sandoz | 10 vials | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Somerset | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Slate | 10 vials | — | — | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Hospira, | 10 vials | — | AP | FDA listed |
| Cisatracurium besylate 2 mg/mL | Caplin | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 2 mg/mL | Camber | 10 vials | — | AP | FDA listed |
| Cisatracurium Besylate 20 mg/10mL | Eugia | 10 vials | — | — | FDA listed |
| Cisatracurium Besylate 20 mg/10mL | Meitheal | 10 vials | — | AP | FDA listed |
| Cisatracurium Besylate 10 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Cisatracurium Besylate 10 mg/mL | Hospira, | 10 vials | — | AP | FDA listed |
| cisatracurium besylate 10 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Cisatracurium Besylate 10 mg/mL | Camber | 10 vials | — | AP | FDA listed |
| Cisatracurium 10 mg/mL | Fresenius | 10 vials | — | AP | FDA listed |
| Cisatracurium besylate 10 mg/mL | Caplin | 1 vial | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Cisatracurium Besylate Injection — that fall in the same broad treatment class (neuromuscular blocking agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other analgesia/addiction shortages
Cisatracurium Besylate Injection shortage FAQs
Is Cisatracurium Besylate Injection in shortage?
Which products are affected?
When will Cisatracurium Besylate Injection be available again?
Can I still get Cisatracurium Besylate somewhere?
What should I do if I take Cisatracurium Besylate Injection?
Still have a question about the Cisatracurium Besylate Injection shortage?
Ask a pharmacist about this shortage →View Cisatracurium Besylate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.